| Diffuse Large B-Cell Lymphoma
Monjuvi vs Yescarta
Side-by-side clinical, coverage, and cost comparison for diffuse large b-cell lymphoma.Deep comparison between: Monjuvi vs Yescarta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsYescarta has a higher rate of injection site reactions vs Monjuvi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Yescarta but not Monjuvi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Monjuvi
Yescarta
At A Glance
IV infusion
Every 2 weeks
CD19-directed monoclonal antibody
IV infusion
Single infusion
CD19-directed CAR T cell immunotherapy
Indications
- Diffuse Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
- Mediastinal (Thymic) Large B-Cell Lymphoma
- High grade B-cell lymphoma
- Lymphoma, Follicular
Dosing
Diffuse Large B-Cell Lymphoma 12 mg/kg IV; Cycle 1: Days 1, 4, 8, 15, and 22; Cycles 2-3: Days 1, 8, 15, and 22; Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle; in combination with lenalidomide for up to 12 cycles, then MONJUVI as monotherapy until disease progression or unacceptable toxicity.
Diffuse Large B-Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, High grade B-cell lymphoma Target dose 2 x 10^6 CAR-positive viable T cells per kg body weight (max 2 x 10^8 cells) as a single IV infusion; pretreat with cyclophosphamide 500 mg/m2 IV and fludarabine 30 mg/m2 IV on days -5, -4, and -3 before infusion.
Lymphoma, Follicular Target dose 2 x 10^6 CAR-positive viable T cells per kg body weight (max 2 x 10^8 cells) as a single IV infusion; pretreat with cyclophosphamide 500 mg/m2 IV and fludarabine 30 mg/m2 IV on days -5, -4, and -3 before infusion.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Neutropenia, fatigue, anemia, diarrhea, thrombocytopenia, cough, pyrexia, peripheral edema, respiratory tract infection, decreased appetite
Serious Infections (including pneumonia, febrile neutropenia), cerebrovascular accident, respiratory failure, progressive multifocal leukoencephalopathy, sudden death
Most common (>=30%) CRS, fever, hypotension, encephalopathy, fatigue, tachycardia, headache, nausea, febrile neutropenia, diarrhea, musculoskeletal pain, infections with pathogen unspecified, chills, decreased appetite
Serious CRS, fever, encephalopathy, hypotension, infection with unspecified pathogen, pneumonia, febrile neutropenia, cardiac arrhythmia, cardiac failure, aphasia, hypoxia
Postmarketing Spinal cord edema, myelitis, quadriplegia, dysphagia, status epilepticus, infusion related reactions, T cell malignancies
Pharmacology
Tafasitamab-cxix is an Fc-modified CD19-directed monoclonal antibody that mediates B-cell lysis through apoptosis, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP); in combination with lenalidomide, it demonstrates increased ADCC activity in DLBCL tumor cells.
CD19-directed genetically modified autologous T cell immunotherapy; upon engagement with CD19-expressing target cells, the CD28 and CD3-zeta co-stimulatory domains activate downstream signaling cascades leading to T cell activation, proliferation, and killing of CD19-expressing cancer cells and normal B cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Monjuvi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Yescarta
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Monjuvi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Yescarta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Monjuvi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Yescarta
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
MonjuviView full Monjuvi profile
YescartaView full Yescarta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.